Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 459

1.

Soluble epoxide hydrolase inhibition and gene deletion are protective against myocardial ischemia-reperfusion injury in vivo.

Motoki A, Merkel MJ, Packwood WH, Cao Z, Liu L, Iliff J, Alkayed NJ, Van Winkle DM.

Am J Physiol Heart Circ Physiol. 2008 Nov;295(5):H2128-34. doi: 10.1152/ajpheart.00428.2008. Epub 2008 Oct 3.

2.

Effects of the selective EET antagonist, 14,15-EEZE, on cardioprotection produced by exogenous or endogenous EETs in the canine heart.

Gross GJ, Gauthier KM, Moore J, Falck JR, Hammock BD, Campbell WB, Nithipatikom K.

Am J Physiol Heart Circ Physiol. 2008 Jun;294(6):H2838-44. doi: 10.1152/ajpheart.00186.2008. Epub 2008 Apr 25.

3.

Inhibition of soluble epoxide hydrolase by trans-4- [4-(3-adamantan-1-yl-ureido)-cyclohexyloxy]-benzoic acid is protective against ischemia-reperfusion injury.

Chaudhary KR, Abukhashim M, Hwang SH, Hammock BD, Seubert JM.

J Cardiovasc Pharmacol. 2010 Jan;55(1):67-73. doi: 10.1097/FJC.0b013e3181c37d69.

4.

Inhibition of soluble epoxide hydrolase preserves cardiomyocytes: role of STAT3 signaling.

Merkel MJ, Liu L, Cao Z, Packwood W, Young J, Alkayed NJ, Van Winkle DM.

Am J Physiol Heart Circ Physiol. 2010 Feb;298(2):H679-87. doi: 10.1152/ajpheart.00533.2009. Epub 2009 Dec 11.

5.

Soluble epoxide hydrolase: a novel therapeutic target in stroke.

Zhang W, Koerner IP, Noppens R, Grafe M, Tsai HJ, Morisseau C, Luria A, Hammock BD, Falck JR, Alkayed NJ.

J Cereb Blood Flow Metab. 2007 Dec;27(12):1931-40. Epub 2007 Apr 18.

6.

Soluble epoxide hydrolase gene deletion is protective against experimental cerebral ischemia.

Zhang W, Otsuka T, Sugo N, Ardeshiri A, Alhadid YK, Iliff JJ, DeBarber AE, Koop DR, Alkayed NJ.

Stroke. 2008 Jul;39(7):2073-8. doi: 10.1161/STROKEAHA.107.508325. Epub 2008 Mar 27.

7.

Soluble epoxide hydrolase: a new target for cardioprotection.

Gross GJ, Nithipatikom K.

Curr Opin Investig Drugs. 2009 Mar;10(3):253-8. Review.

8.

Differential effects of soluble epoxide hydrolase inhibition and CYP2J2 overexpression on postischemic cardiac function in aged mice.

Chaudhary KR, Zordoky BN, Edin ML, Alsaleh N, El-Kadi AO, Zeldin DC, Seubert JM.

Prostaglandins Other Lipid Mediat. 2013 Jul-Aug;104-105:8-17. doi: 10.1016/j.prostaglandins.2012.08.001. Epub 2012 Aug 16.

9.

Cardioprotective effect of a dual acting epoxyeicosatrienoic acid analogue towards ischaemia reperfusion injury.

Batchu SN, Lee SB, Qadhi RS, Chaudhary KR, El-Sikhry H, Kodela R, Falck JR, Seubert JM.

Br J Pharmacol. 2011 Feb;162(4):897-907. doi: 10.1111/j.1476-5381.2010.01093.x.

10.

Novel soluble epoxide hydrolase inhibitor protects mitochondrial function following stress.

Batchu SN, Lee SB, Samokhvalov V, Chaudhary KR, El-Sikhry H, Weldon SM, Seubert JM.

Can J Physiol Pharmacol. 2012 Jun;90(6):811-23. doi: 10.1139/y2012-082. Epub 2012 May 24.

PMID:
22624559
11.
13.

Soluble Epoxide Hydrolase Deficiency or Inhibition Attenuates MPTP-Induced Parkinsonism.

Qin X, Wu Q, Lin L, Sun A, Liu S, Li X, Cao X, Gao T, Luo P, Zhu X, Wang X.

Mol Neurobiol. 2015 Aug;52(1):187-95. doi: 10.1007/s12035-014-8833-3. Epub 2014 Aug 17.

PMID:
25128026
14.

Adenosine A2A receptor modulates vascular response in soluble epoxide hydrolase-null mice through CYP-epoxygenases and PPARĪ³.

Nayeem MA, Pradhan I, Mustafa SJ, Morisseau C, Falck JR, Zeldin DC.

Am J Physiol Regul Integr Comp Physiol. 2013 Jan 1;304(1):R23-32. doi: 10.1152/ajpregu.00213.2012. Epub 2012 Nov 14.

15.

Soluble epoxide hydrolase deficiency attenuates neointima formation in the femoral cuff model of hyperlipidemic mice.

Revermann M, Schloss M, Barbosa-Sicard E, Mieth A, Liebner S, Morisseau C, Geisslinger G, Schermuly RT, Fleming I, Hammock BD, Brandes RP.

Arterioscler Thromb Vasc Biol. 2010 May;30(5):909-14. doi: 10.1161/ATVBAHA.110.204099. Epub 2010 Mar 11.

16.

Inhibition of soluble epoxide hydrolase does not protect against endotoxin-mediated hepatic inflammation.

Fife KL, Liu Y, Schmelzer KR, Tsai HJ, Kim IH, Morisseau C, Hammock BD, Kroetz DL.

J Pharmacol Exp Ther. 2008 Dec;327(3):707-15. doi: 10.1124/jpet.108.142398. Epub 2008 Sep 24.

17.

Role of B-type natriuretic peptide in epoxyeicosatrienoic acid-mediated improved post-ischaemic recovery of heart contractile function.

Chaudhary KR, Batchu SN, Das D, Suresh MR, Falck JR, Graves JP, Zeldin DC, Seubert JM.

Cardiovasc Res. 2009 Jul 15;83(2):362-70. doi: 10.1093/cvr/cvp134. Epub 2009 Apr 28.

18.

Soluble epoxide hydrolase activity determines the severity of ischemia-reperfusion injury in kidney.

Lee JP, Yang SH, Lee HY, Kim B, Cho JY, Paik JH, Oh YJ, Kim DK, Lim CS, Kim YS.

PLoS One. 2012;7(5):e37075. doi: 10.1371/journal.pone.0037075. Epub 2012 May 10.

19.

Epoxyeicosatrienoic acids limit damage to mitochondrial function following stress in cardiac cells.

Katragadda D, Batchu SN, Cho WJ, Chaudhary KR, Falck JR, Seubert JM.

J Mol Cell Cardiol. 2009 Jun;46(6):867-75. doi: 10.1016/j.yjmcc.2009.02.028. Epub 2009 Mar 12.

PMID:
19285984
20.

Soluble epoxide hydrolase inhibitors and heart failure.

Qiu H, Li N, Liu JY, Harris TR, Hammock BD, Chiamvimonvat N.

Cardiovasc Ther. 2011 Apr;29(2):99-111. doi: 10.1111/j.1755-5922.2010.00150.x. Review.

Supplemental Content

Support Center